A high mutation frequency of p53 is observed in nearly all non-HPV cancers, except in cervical tumors, in which p53 is almost invariably the wild-type, indicating that the inhibitory effect of E6 is analogous to an inactivating mutant [35]. This evidence concerns the gene TP53 and uterine cervix neoplasm.